The SEC has issued a cease and desist order to FibroGen Inc, a biotech company headquartered in San Francisco, finding that it, mainly through its chief medical officer, made false and/or materially misleading disclosures in a range of forums, including a high-profile industry presentation, multiple SEC filings, an earnings call,
SEC brings action against biotech firm for false and misleading statements
The SEC found fault with the firm for how it reported cardiovascular safety results to investors regarding its drug, Roxadustat.